| Assay ID | Title | Year | Journal | Article |
|---|
| AID748911 | Half life in po dosed rat | 2013 | Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
| Recent advances in malaria drug discovery. |
| AID1579673 | Antimalarial activity against Plasmodium berghei infected in po dosed NMRI mouse assessed as reduction in parasite growth administered daily for 3 consecutive days by flow cytometric analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510729 | Binding affinity to human recombinant opiate kappa receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510682 | Binding affinity to human recombinant androgen receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579699 | Apparent clearance in human at 300 mg/kg, po and measured up to 96 to 144 hrs by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510733 | Binding affinity to human recombinant serotonin 5-HT1A receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579652 | AUC (infinity) in mouse at 5.4 mg/kg, iv and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579696 | Inhibition of human ERG by binding assay | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510908 | Intrinsic clearance in human liver microsome | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579692 | Oral bioavailability in Wistar Hannover rat at 10 mg/kg by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1375194 | Resistance index, ratio of IC50 for drug-resistant Plasmodium falciparum Dd2 harboring ATP4 P990R/D124Y double mutant to IC50 for wild type Plasmodium falciparum Dd2 | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
| Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ |
| AID1579681 | Antimalarial activity against Plasmodium berghei infected in NMRI mouse assessed as mean survival days at 100 mg/kg, po administered once and measured up to 30 days | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510723 | Binding affinity to human recombinant neurotensin NT1 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510684 | Binding affinity to rat benzodiazepine receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510690 | Binding affinity to human recombinant cholecystokinin A receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510661 | Antimalarial activity against chloroquine, mefloquine and pyrimethamine-resistant Plasmodium falciparum TM91C235 after 48 hrs incubation by [3H]hypoxanthine incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510697 | Binding affinity to human recombinant dopamine D2 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510923 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as cure rate at 10 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measured on day 30 post | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID482589 | Clearance in mouse at 5 mg/kg, iv | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
| Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. |
| AID1579660 | Half life in rat at 5 mg/kg, iv and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579695 | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 4 days by XTT assay | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510932 | Antimalarial activity against NITD678-resistant Plasmodium falciparum Dd2 Clone3 bearing P-type ATPase4 I203M and I263V mutations after 72 hrs by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510896 | Volume of distribution at steady state in Wistar rat at 5 mg/kg, iv | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510701 | Binding affinity to human recombinant endothelin A receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510654 | Selectivity index, ratio of CC50 for human BHK21 cells to IC50 for Plasmodium falciparum after 48 hrs incubation by [3H]hypoxanthin incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579659 | AUC (infinity) in rat at 23.7 mg/kg, po and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510943 | Partition coefficient, log P of the compound at pH 7.4 | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510721 | Binding affinity to human recombinant neuropeptide Y1 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID482418 | Inhibition of CYP2C9 in human liver microsome by LC-MS/MS analysis | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
| Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. |
| AID1579704 | Metabolic stability in human assessed as paren compound remaining at 300 mg/kg, po by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510929 | Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone3 bearing P-type ATPase4 D1247Y mutations after 72 hrs by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510900 | Tmax in Wistar rat at 23.7 mg/kg, po | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510679 | Binding affinity to human recombinant alpha-2a receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579712 | Antimalarial activity against Plasmodium falciparum infected in human assessed as parasite clearance time at 30 mg/kg, po | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510915 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as cure rate at 30 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 30 days post infection | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID772515 | Antimalarial activity against gametocytic stage of Plasmodium berghei infected in blood assessed as inhibition of ookinete formation at 10 uM after 24 hrs by Giemsa staining-based microscopic analysis relative to control | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Using genetic methods to define the targets of compounds with antimalarial activity. |
| AID510940 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia dosed in ETPGS formulation 1 day post infection measured 72 hrs post infection | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510934 | Antimalarial activity against Plasmodium falciparum Dd2 containing attB site inserted in parasite genome and using EF1-alpha promoter driven expressing wild type ATP4 after 72 hrs by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510691 | Binding affinity to human recombinant cholecystokinin B receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510731 | Binding affinity to human recombinant PDE3 | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1849704 | Antimalarial activity against Plasmodium falciparum NF54 | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins. |
| AID510688 | Binding affinity to rat N-type calcium channel | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510712 | Binding affinity to human recombinant histamine H3 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510667 | Cytotoxicity against human BHK21 cells after 4 days by XTT assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510666 | Cytotoxicity against human HepG2 cells after 4 days by XTT assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510725 | Binding affinity to human recombinant nicotinic (CNS) receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510730 | Binding affinity to human recombinant opiate mu receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510948 | Toxicity in Plasmodium berghei GFP ANKA infected NMRI mice (Mus musculus) assessed as reduction in parasitemia dosed in ETPGS formulation 1 day postinfection measured 72 hrs post infection | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579710 | Antimalarial activity against Plasmodium falciparum infected in human assessed as reduction in parasite growth at 30 mg/kg, po administered daily for 3 consecutive day and measured on day 5 relative to control | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510664 | Cytotoxicity against human C6 cells after 4 days by XTT assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579677 | Antimalarial activity against Plasmodium berghei infected in NMRI mouse assessed as reduction in parasite growth at 30 mg/kg, po administered daily for 3 consecutive days by flow cytometric analysis relative to control | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510928 | Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone2 bearing P-type ATPase4 T418N and P990R mutations after 72 hrs by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1604218 | Antiparasitic activity against Plasmodium falciparum infected in mouse | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181 | New dimensions in the field of antimalarial research against malaria resurgence. |
| AID510931 | Antimalarial activity against NITD678-resistant Plasmodium falciparum Dd2 Clone2 bearing P-type ATPase4 A184S and P990Y mutations after 72 hrs by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579672 | Antimalarial activity against Plasmodium berghei infected in NMRI mouse assessed as reduction in parasite growth at 5.3 mg/kg, po administered daily for 3 consecutive days by flow cytometric analysis relative to control | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID748909 | Antimalarial activity against Plasmodium berghei infected in po dosed mouse | 2013 | Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
| Recent advances in malaria drug discovery. |
| AID1579708 | Drug recovery in feces of po dosed human by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510743 | Volume of distribution at steady state in CD1 mouse at 5.4 mg/kg, iv | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510659 | Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum 7G8 after 48 hrs incubation by [3H]hypoxanthine incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510903 | Elimination half life in Wistar rat at 23.7 mg/kg, po | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510698 | Binding affinity to human recombinant dopamine D3 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510651 | Selectivity index, ratio of CC50 for human C6 cells to IC50 for Plasmodium falciparum after 48 hrs incubation by [3H]hypoxanthin incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579709 | Antimalarial activity against Plasmodium vivax infected in human assessed as reduction in parasite growth at 30 mg/kg, po administered daily for 3 consecutive day and measured on day 5 relative to control | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID772523 | Antiplasmodial activity against Plasmodium berghei infected mouse model assessed as reduction in parasitemia at 30 mg/kg, po | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Cell-based medicinal chemistry optimization of high-throughput screening (HTS) hits for orally active antimalarials. Part 1: challenges in potency and absorption, distribution, metabolism, excretion/pharmacokinetics (ADME/PK). |
| AID510920 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 10 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measured 96 hrs post inf | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID772530 | Half life in mouse liver microsomes | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Cell-based medicinal chemistry optimization of high-throughput screening (HTS) hits for orally active antimalarials. Part 1: challenges in potency and absorption, distribution, metabolism, excretion/pharmacokinetics (ADME/PK). |
| AID482413 | Antimalarial activity against drug-sensitive Plasmodium falciparum NF54 infected in human erythrocytes after 48 hrs by [3H]hypoxanthine assay | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
| Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. |
| AID1579651 | Volume of distribution at steady state in mouse at 5.4 mg/kg, iv and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579693 | Oral bioavailability in Beagle dog at 3 mg/kg by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510740 | Binding affinity to human recombinant vasopressin V1a receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1375186 | Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring ATP4 P990R/D124Y double mutant | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
| Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ |
| AID510736 | Binding affinity to human recombinant serotonin 5HT2C receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510696 | Binding affinity to human recombinant dopamine D1 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510676 | Binding affinity to human recombinant adrenergic beta2 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579690 | Tmax in Wistar Hannover rat at 10 mg/kg, po by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510906 | Intrinsic clearance in dog liver microsome | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510706 | Binding affinity to rat Gip receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510894 | Elimination half life in CD1 mouse at 24.6 mg/kg, po | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579703 | AUC (0 to 24 hrs) in human at 150 mg/kg, po for 3 days and measured on day 3 by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579684 | Volume of distribution in Wistar Hannover rat at 5 mg/kg, iv by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510732 | Binding affinity to human recombinant PDE4D | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510703 | Binding affinity to human recombinant ERalpha | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1849713 | In vivo antimalarial activity against Plasmodium falciparum infected in NMRI mouse | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins. |
| AID510942 | Solubility in pH 6.8 nuffer | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510914 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 100 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510912 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 10 mg/kg, perorally administered as single dose as single dose 24 hrs post infection for 1 day measured 72 hrs post infection | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510692 | Binding affinity to human recombinant COX1 | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510738 | Binding affinity to human recombinant serotonin transporter | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579663 | Oral bioavailability in rat at 23.7 mg/kg and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510693 | Binding affinity to human recombinant COX2 | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510904 | Intrinsic clearance in mouse liver microsome | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510694 | Binding affinity to human recombinant CRF1 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510683 | Binding affinity to human recombinant angiotensin2 AT1 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510660 | Antimalarial activity against chloroquine, mefloquine and pyrimethamine-resistant Plasmodium falciparum TM90C2A after 48 hrs incubation by [3H]hypoxanthine incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510926 | Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510907 | Intrinsic clearance in monkey liver microsome | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510922 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 50 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measured 96 hrs post inf | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510653 | Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for Plasmodium falciparum after 48 hrs incubation by [3H]hypoxanthin incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510937 | Antimalarial activity against Plasmodium falciparum Dd2 containing attB site inserted in parasite genome and using CAM promoter driven expressing ATP4 D1247Y mutant after 72 hrs by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510670 | Inhibition of human ERG at 30 uM by patch clamp method | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510742 | AUC (0 to infinity) in CD1 mouse at 5.4 mg/kg, iv | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579682 | Clearance in Wistar Hannover rat at 5 mg/kg, iv by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510717 | Binding affinity to human recombinant muscarinic M1 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510702 | Binding affinity to human recombinant endothelin B receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510699 | Binding affinity to human recombinant dopamine D4.4 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579707 | Half life in human | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510656 | Antimalarial activity against Plasmodium falciparum 3D7 after 48 hrs incubation by [3H]hypoxanthin incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510944 | Inhibition of protein synthesis in NITD609-resistant Plasmodium falciparum Dd2 Clone1 within 1 hrs by [35S]Met/Cys incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID482419 | Inhibition of CYP3A4 in human liver microsome by LC-MS/MS analysis | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
| Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. |
| AID510689 | Binding affinity to human recombinant cannabinoid 1 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510711 | Binding affinity to human recombinant histamine H2 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510663 | Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum V1/S after 48 hrs incubation by [3H]hypoxanthine incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510927 | Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone1 bearing P-type ATPase4 I398F and P990R mutations after 72 hrs by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510938 | Antimalarial activity against Plasmodium falciparum Dd2 containing attB site inserted in parasite genome and using CAM promoter driven expressing ATP4 I398F/P990R mutant after 72 hrs by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579702 | Cmax in human at 150 mg/kg, po for 3 days and measured on day 3 by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510893 | Oral bioavailability in CD1 mouse at 24.6 mg/kg | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510925 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as cure rate at 50 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measured on day 30 post | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510648 | Antimalarial activity against Plasmodium vivax isolates after 42 hrs | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510713 | Binding affinity to human recombinant melanocortin MC3 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579689 | Cmax in Beagle dog at 3 mg/kg, po by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510718 | Binding affinity to human recombinant muscarinic M2 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510708 | Binding affinity to human recombinant glucocorticoid receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510916 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as cure rate at 100 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 30 days post infection | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510913 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 30 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510705 | Binding affinity to human recombinant GABAA receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579668 | Antimalarial activity against Plasmodium falciparum TM90C2A infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs followed by addition of [3H]-hypoxanthine and measured after 24 hrs by liquid scintill | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579670 | Antimalarial activity against Plasmodium falciparum D6 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs followed by addition of [3H]-hypoxanthine and measured after 24 hrs by liquid scintillation | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510695 | Binding affinity to human recombinant CRF2alpha receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579665 | Antimalarial activity against Plasmodium falciparum K1 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs followed by addition of [3H]-hypoxanthine and measured after 24 hrs by liquid scintillation | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510669 | Inhibition of human ERG | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579698 | AUC (0 to 24 hrs) in human at 300 mg/kg, po by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510935 | Antimalarial activity against Plasmodium falciparum Dd2 containing attB site inserted in parasite genome and using EF1-alpha promoter driven expressing ATP4 D1247Y mutant after 72 hrs by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510905 | Intrinsic clearance in rat liver microsome | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1375190 | Antimalarial activity against wild type Plasmodium falciparum Dd2 | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
| Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ |
| AID510681 | Binding affinity to human recombinant alpha2c receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510658 | Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum W2 | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510901 | AUC (0 to infinity) in Wistar rat at 23.7 mg/kg, po | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510946 | Mutagenic activity in Salmonella Typhimurium by Ames test | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510662 | Antimalarial activity against Plasmodium falciparum D6 after 48 hrs incubation by [3H]hypoxanthin incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID777546 | Clearance in CD1 mouse at 5.4 mg/kg, iv by LC-MS analysis | 2013 | ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
| Pharmacokinetics, metabolism, and |
| AID1579691 | Tmax in Beagle dog at 3 mg/kg, po by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID772526 | Oral bioavailability in mouse | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Cell-based medicinal chemistry optimization of high-throughput screening (HTS) hits for orally active antimalarials. Part 1: challenges in potency and absorption, distribution, metabolism, excretion/pharmacokinetics (ADME/PK). |
| AID1604332 | Antiparasitic activity against Toxoplasma gondii infected in human HuH7 cells | 2019 | European journal of medicinal chemistry, Dec-01, Volume: 183 | Recent progress on anti-Toxoplasma drugs discovery: Design, synthesis and screening. |
| AID510674 | Binding affinity to human recombinant adenosine transporter | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510668 | Inhibition of human ERG at 30 uM | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510741 | Binding affinity to human recombinant vasopressin V2 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510671 | Inhibition of human ERG by patch clamp method | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510918 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 30 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measure | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579658 | AUC (infinity) in rat at 5 mg/kg, iv and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579678 | Antimalarial activity against Plasmodium berghei infected in NMRI mouse assessed as reduction in parasite growth at 50 mg/kg, po administered daily for 3 consecutive days by flow cytometric analysis relative to control | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579661 | Half life in rat at 23.7 mg/kg, po and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510686 | Binding affinity to human recombinant bradykinin B2 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510910 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 30 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579687 | Half life in Beagle dog at 1 mg/kg, iv by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510898 | Elimination half life in Wistar rat at 5 mg/kg, iv | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579653 | Clearance in mouse at 5.4 mg/kg, iv and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510685 | Binding affinity to human recombinant bradykinin B1 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID772525 | Antiplasmodial activity against blood stage form of Plasmodium falciparum NF54 | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Cell-based medicinal chemistry optimization of high-throughput screening (HTS) hits for orally active antimalarials. Part 1: challenges in potency and absorption, distribution, metabolism, excretion/pharmacokinetics (ADME/PK). |
| AID510722 | Binding affinity to human recombinant neuropeptide Y2 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510716 | Binding affinity to human recombinant motilin receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510720 | Binding affinity to human recombinant neurokinin NK1 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510739 | Binding affinity to human recombinant thromboxane A2 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579697 | Inhibition of human ERG by patch clamp method | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1849705 | Antimalarial activity against Plasmodium falciparum K1 | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins. |
| AID510650 | Antimalarial activity against Plasmodium falciparum 3D7 assessed as parasite growth inhibition at 1.6 nM after24 hrs by [3H]hypoxanthin incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510715 | Binding affinity to human recombinant MAOM | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579671 | Antimalarial activity against Plasmodium falciparum V1/S infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs followed by addition of [3H]-hypoxanthine and measured after 24 hrs by liquid scintillati | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579657 | Oral bioavailability in mouse at 24.6 mg/kg and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579669 | Antimalarial activity against Plasmodium falciparum TM91C235 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs followed by addition of [3H]-hypoxanthine and measured after 24 hrs by liquid scintil | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579655 | AUC (infinity) in mouse at 24.6 mg/kg, po and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579717 | Antimalarial activity against Plasmodium vivax infected in human assessed as parasite clearance time at 30 mg/kg, po administered daily for 3 consecutive day and measured on day 5 | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510652 | Selectivity index, ratio of CC50 for human THP1 cells to IC50 for Plasmodium falciparum after 48 hrs incubation by [3H]hypoxanthin incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510897 | Clearance in Wistar rat at 5 mg/kg, iv | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579711 | Half life in human at 30 mg/kg, po | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510710 | Binding affinity to human recombinant histamine H1 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510727 | Binding affinity to human recombinant norepinephrine transporter | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510744 | Clearance in CD1 mouse at 5.4 mg/kg, iv | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579674 | Antimalarial activity against Plasmodium berghei infected in NMRI mouse assessed as reduction in parasite growth at 10 mg/kg, po administered once and measured after 96 hrs by flow cytometric analysis relative to control | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510917 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 10 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measure | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID772524 | Half life in mouse | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Cell-based medicinal chemistry optimization of high-throughput screening (HTS) hits for orally active antimalarials. Part 1: challenges in potency and absorption, distribution, metabolism, excretion/pharmacokinetics (ADME/PK). |
| AID510919 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 50 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measure | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579713 | Antimalarial activity against Plasmodium falciparum infected in po dosed human assessed as reduction in parasite growth | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID748921 | Oral bioavailability in mouse | 2013 | Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
| Recent advances in malaria drug discovery. |
| AID1579688 | Cmax in Wistar Hannover rat at 10 mg/kg, po by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510911 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 100 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579656 | Half life in mouse at 24.6 mg/kg, po and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1907340 | Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as effect on cytosolic sodium concentration at 50 nM measured after 90 mins by SBFI-dye based fluorescence method | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Discovery of spirooxadiazoline oxindoles with dual-stage antimalarial activity. |
| AID510737 | Binding affinity to human recombinant serotonin 5HT3 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1127075 | Antiplasmodial activity against ring stage synchronized Plasmodium falciparum 3D7 infected in erythrocytes assessed as parasitemia level after 48 hrs by flow cytometry relative to control | 2014 | European journal of medicinal chemistry, May-06, Volume: 78 | Synthetic indole and melatonin derivatives exhibit antimalarial activity on the cell cycle of the human malaria parasite Plasmodium falciparum. |
| AID510709 | Binding affinity to human recombinant Ghrelin receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510678 | Binding affinity to human recombinant alpha 1a receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID748926 | Antiplasmodial activity against drug-sensitive Plasmodium falciparum 3D7 | 2013 | Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
| Recent advances in malaria drug discovery. |
| AID510655 | Antimalarial activity against Plasmodium falciparum NF54 after 48 hrs incubation by [3H]hypoxanthin incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579648 | Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs followed by addition of [3H]-hypoxanthine and measured after 24 hrs by liquid scintillatio | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510724 | Binding affinity to human recombinant niacin receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579667 | Antimalarial activity against Plasmodium falciparum 7G8 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs followed by addition of [3H]-hypoxanthine and measured after 24 hrs by liquid scintillatio | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579646 | Half life in human at 300 mg/kg, po by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579666 | Antimalarial activity against Plasmodium falciparum W2 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs followed by addition of [3H]-hypoxanthine and measured after 24 hrs by liquid scintillation | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579645 | Tmax in human at 300 mg/kg, po and measured up to 96 to 144 hrs by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510939 | Antimalarial activity against Plasmodium falciparum assessed as [35S]Met/Cys incorporation by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579715 | Antimalarial activity against Plasmodium vivax infected in human assessed as median parasite clearance time at 30 mg/kg, po administered daily for 3 consecutive day and measured on day 5 | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579664 | Antimalarial activity against Plasmodium falciparum NF54 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs followed by addition of [3H]-hypoxanthine and measured after 24 hrs by liquid scintillati | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510675 | Binding affinity to human recombinant adrenergic beta-1 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510704 | Binding affinity to human recombinant ERbeta | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579705 | Plasma protein binding in human | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510924 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as cure rate at 30 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measured on day 30 post | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510941 | Antimalarial activity against Plasmodium falciparum isolates after 42 hrs | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579647 | Cmax in human at 300 mg/kg, po and measured up to 96 to 144 hrs by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510902 | Oral bioavailability in Wistar rat at 23.7 mg/kg | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579654 | Half life in mouse at 5.4 mg/kg, iv and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID777558 | Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mouse assessed as reduction of parasitemia at 10 mg/kg, po qd administered 3 days by flow cytometric analysis | 2013 | ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
| Pharmacokinetics, metabolism, and |
| AID510745 | Elimination half life in CD1 mouse at 5.4 mg/kg, iv | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510921 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 30 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measured 96 hrs post inf | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510700 | Binding affinity to human recombinant dopamine transporter | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510672 | Binding affinity to human recombinant adenosine 2a receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510933 | Antimalarial activity against Plasmodium falciparum Dd2 containing attB site inserted in parasite genome and expressing parental ATP4 after 72 hrs by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510680 | Binding affinity to human recombinant alpha2b receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510728 | Binding affinity to human recombinant opiate delta receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510734 | Binding affinity to human recombinant serotonin 5-HT2A receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579675 | Antimalarial activity against Plasmodium berghei infected in NMRI mouse assessed as reduction in parasite growth at 100 mg/kg, po administered once and measured after 96 hrs by flow cytometric analysis relative to control | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579714 | Antimalarial activity against Plasmodium falciparum infected in human assessed as median parasite clearance time at 30 mg/kg, po administered daily for 3 consecutive day and measured on day 5 | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510714 | Binding affinity to human recombinant melanocortin MC4 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510673 | Binding affinity to human recombinant adenosine 3 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID777559 | Antiplasmodial activity against Plasmodium falciparum assessed as [3H]-hypoxanthine incorporation after 48 hrs by liquid scintillation counting analysis | 2013 | ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
| Pharmacokinetics, metabolism, and |
| AID748920 | Oral bioavailability in rat | 2013 | Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
| Recent advances in malaria drug discovery. |
| AID1579679 | Antimalarial activity against Plasmodium berghei infected in NMRI mouse assessed as mean survival days at 10 mg/kg, po administered once and measured up to 30 days | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510677 | Binding affinity to human recombinant adrenergic beta3 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579686 | Half life in Wistar Hannover rat at 5 mg/kg, iv by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579683 | Clearance in Beagle dog at 1 mg/kg, iv by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579662 | Clearance in rat at 5 mg/kg, iv or 23.7 mg/kg, po and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579694 | Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 4 days by XTT assay | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID772516 | Antimalarial activity against mature gametocytic stage of Plasmodium falciparum assessed as inhibition of mature gamete exflagellation at 10 uM incubated for 24 hrs prior to exflagellation induction at 21 degC measured after 20 mins by microscopic analysi | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Using genetic methods to define the targets of compounds with antimalarial activity. |
| AID1579676 | Antimalarial activity against Plasmodium berghei infected in NMRI mouse assessed as reduction in parasite growth at 10 mg/kg, po administered daily for 3 consecutive days by flow cytometric analysis relative to control | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510892 | AUC (0 to infinity) in CD1 mouse at 24.6 mg/kg, po | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510687 | Binding affinity to rat L-type calcium channel | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1849700 | Dissociation constant, pKa of compound | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins. |
| AID510891 | Tmax in CD1 mouse at 24.6 mg/kg, po | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579701 | AUC (0 to 24 hrs) in human at 150 mg/kg, po for 3 days and measured on day 1 by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579680 | Antimalarial activity against Plasmodium berghei infected in NMRI mouse assessed as mean survival days at 30 mg/kg, po administered once and measured up to 30 days | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID748912 | Half life in po dosed mouse | 2013 | Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
| Recent advances in malaria drug discovery. |
| AID510707 | Binding affinity to human recombinant glucagon receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1849708 | Inhibition of human ERG | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins. |
| AID482420 | Inhibition of CYP2D6 in human liver microsome by LC-MS/MS analysis | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
| Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. |
| AID510746 | Cmax in CD1 mouse at 24.6 mg/kg, po | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510665 | Cytotoxicity against human THP1 cells after 4 days by XTT assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579650 | Tmax in mouse at 24.6 mg/kg, po and measured up to 24 hrs by LC/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510657 | Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 after 48 hrs incubation by [3H]hypoxanthine incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510945 | Inhibition of protein synthesis in NITD609-resistant Plasmodium falciparum Dd2 Clone3 within 1 hrs by [35S]Met/Cys incorporation assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1579700 | Cmax in human at 150 mg/kg, po for 3 days and measured on day 1 by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID1579685 | Volume of distribution in Beagle dog at 1 mg/kg, iv by LC-MS/MS analysis | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510909 | Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 10 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID1907343 | Inhibition of plasmodium falciparum 3D7 ATP4 ATPase activity under high-soidum conditions at 125 nM | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Discovery of spirooxadiazoline oxindoles with dual-stage antimalarial activity. |
| AID1579716 | Antimalarial activity against Plasmodium falciparum infected in human assessed as median clearance time at 30 mg/kg, po administered daily for 3 consecutive day and measured on day 5 | 2019 | Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
| The Development Process for Discovery and Clinical Advancement of Modern Antimalarials. |
| AID510719 | Binding affinity to human recombinant muscarinic M3 receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510895 | AUC (0 to infinity) in Wistar rat at 5 mg/kg, iv | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510930 | Antimalarial activity against NITD678-resistant Plasmodium falciparum Dd2 Clone1 bearing P-type ATPase4 G223R mutations after 72 hrs by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510735 | Binding affinity to human recombinant serotonin 5-HT2B receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510936 | Antimalarial activity against Plasmodium falciparum Dd2 containing attB site inserted in parasite genome and using EF1-alpha promoter driven expressing ATP4 I398F/P990R mutant after 72 hrs by SYBR green based fluorescence assay | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510726 | Binding affinity to human recombinant NMDA receptor | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| AID510899 | Cmax in Wistar rat at 23.7 mg/kg, po | 2010 | Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
| Spiroindolones, a potent compound class for the treatment of malaria. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |